Fungal Superbug Treatment: A Breakthrough in Fighting Resistance Infections
- Sep 22
- 2 min read
In a major step forward for global health, scientists have announced the discovery of a new class of antifungal compounds that could turn the tide against deadly, drug-resistant infections. The urgency for fungal superbug treatment has been mounting for years, largely due to the emergence of resilient pathogens like Candida auris, a fungus that thrives at human body temperature and can be extremely drug-resistant.
For patients with compromised immune systems, such as those undergoing cancer chemotherapy, C. auris can cause severe and often fatal infections of the lungs, bloodstream, and nervous system. Its rise has placed it at the top of the World Health Organization's list of priority fungal pathogens.
The challenge in developing effective antifungals has always been a biological one: fungi are more closely related to humans than bacteria, meaning drugs that kill fungi often pose a risk to human cells. This has resulted in a very limited arsenal of treatments, with only about three classes of antifungal drugs currently on the market.
However, new research offers significant hope. A team at McMaster University has identified a new drug class they've named "coniotins". These molecules were isolated from a fungus found in the university's own greenhouse and have shown powerful activity against C. auris and other fungal pathogens, all while showing no toxicity to human cells.
What makes coniotins so promising is their unique method of attack. Unlike existing drugs that target proteins or membranes, coniotins disrupt the fungal cell wall—the protective outer shell essential for the organism's survival. This novel approach is part of a broader push in scientific research exploring new ways to combat fungal infections, including advancements in single-molecule imaging and other drug discoveries like olorofim, which also works differently from current medications.
Another new class of antifungal compounds, highlighted by King's College London, has also proven effective at disrupting fungal biofilms without toxicity.
The discovery of coniotins was made possible through an innovative screening process called prefractionation, which helps scientists find previously hidden molecules in complex chemical mixtures. The lead researcher, Professor Gerry Wright, notes that his team has only screened about five percent of their chemical library, suggesting that many more discoveries may lie ahead.
The next steps for the McMaster team involve producing coniotins on a larger scale and developing a formula suitable for intravenous delivery, bringing this breakthrough one step closer to clinical use. These developments signal a new era of optimism for patients suffering from dangerous fungal infections that have so far resisted treatment.
🔖 Sources
Comments